ADMA Biologics ( (ADMA) ) has released a notification of late filing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ADMA Biologics, Inc. has announced a delay in filing its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the recent change in the company’s independent registered public accounting firm, with KPMG LLP taking over after the resignation of the previous firm. This transition necessitated additional time to test and document internal controls, particularly those involving third-party service providers. ADMA Biologics expects to file the delayed report by March 18, 2025, within the 15-day extension period allowed. The company has indicated that there may be significant changes in financial results compared to the previous year, although no specific estimates have been provided. The notification was signed by Adam S. Grossman, the President and CEO, who assured ongoing compliance efforts.
More about ADMA Biologics
YTD Price Performance: -8.79%
Average Trading Volume: 2,282,025
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.87B
See more insights into ADMA stock on TipRanks’ Stock Analysis page.